Timothy Rolph - Akero Therapeutics CoFounder Officer
| AKRO Stock | USD 32.17 1.01 3.24% |
Insider
Timothy Rolph is CoFounder Officer of Akero Therapeutics
| Age | 70 |
| Address | 601 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 487 6488 |
| Web | https://akerotx.com |
Timothy Rolph Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timothy Rolph against Akero Therapeutics stock is an integral part of due diligence when investing in Akero Therapeutics. Timothy Rolph insider activity provides valuable insight into whether Akero Therapeutics is net buyers or sellers over its current business cycle. Note, Akero Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Akero Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timothy Rolph over three months ago Disposition of 619 shares by Timothy Rolph of Akero Therapeutics at 28.33 subject to Rule 16b-3 | ||
Timothy Rolph over six months ago Disposition of 619 shares by Timothy Rolph of Akero Therapeutics at 28.33 subject to Rule 16b-3 |
Akero Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2317) % which means that it has lost $0.2317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.359) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 28th of November 2024, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (0.95).Similar Executives
| Showing other executives | INSIDER Age | ||
| Henric Bjarke | Inozyme Pharma | 57 | |
| Desiree DDS | Passage Bio | N/A | |
| Simona King | Passage Bio | 52 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Fang PharmD | Black Diamond Therapeutics | 37 | |
| Path FRCP | Revolution Medicines | 61 | |
| Teresa McCarthy | Avidity Biosciences | 60 | |
| Mark MD | Passage Bio | 60 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Jack Anders | Revolution Medicines | 47 | |
| Christopher Roberts | Black Diamond Therapeutics | 54 | |
| MSc MBA | Passage Bio | 55 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Marianne Mancini | Viking Therapeutics | 59 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.23 |
Akero Therapeutics Leadership Team
Elected by the shareholders, the Akero Therapeutics' board of directors comprises two types of representatives: Akero Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akero. The board's role is to monitor Akero Therapeutics' management team and ensure that shareholders' interests are well served. Akero Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akero Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Rolph, CoFounder Officer | ||
| Patrick Lamy, Senior Strategy | ||
| Andrew MD, CEO President | ||
| Scott Gangloff, Chief Officer | ||
| Catriona Yale, Executive Officer | ||
| William JD, CFO, VP | ||
| David JD, Vice Legal | ||
| Dr JD, Executive CoFounder | ||
| John Schembri, Senior Finance |
Akero Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akero Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.49 B | ||||
| Shares Outstanding | 69.8 M | ||||
| Shares Owned By Insiders | 5.34 % | ||||
| Shares Owned By Institutions | 94.66 % | ||||
| Number Of Shares Shorted | 3.62 M | ||||
| Price To Earning | (7.43) X | ||||
| Price To Book | 2.95 X | ||||
| EBITDA | (148.63 M) |
Pair Trading with Akero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akero Stock
| 0.76 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Akero Stock
| 0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.77 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.76 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.66 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.